AbbVie: Irritable Bowel Syndrome trials

The registry lists 15 Irritable Bowel Syndrome studies with AbbVie as lead sponsor. 1 are open to participants now and 12 have results posted.

Phase 1 1Phase 2 4Phase 3 7Phase 4 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)Enrolling by invitationNCT04880876Phase 3
• Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)CompletedNCT04026113Phase 3Results posted
• Eluxadoline Bile Acid Malabsorption (BAM) StudyCompletedNCT03441581Phase 4Results posted
• Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide UseCompletedNCT02959983Phase 4Results posted
• An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic ConstipationCompletedNCT02590432Phase 4Results posted
• A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With ConstipationTerminatedNCT02559817Phase 2Results posted
• Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)CompletedNCT01553747Phase 3Results posted
• Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)CompletedNCT01553591Phase 3Results posted
• Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mgTerminatedNCT01358708Phase 3Results posted
• Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With DiarrheaCompletedNCT01130272Phase 2Results posted
• Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With ConstipationCompletedNCT00948818Phase 3Results posted
• An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With ConstipationCompletedNCT00765999Phase 3Results posted
• Safety and Efficacy of Oral AGN 203818 for the Relief of Irritable Bowel Syndrome PainTerminatedNCT00441766Phase 2Results posted
• Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in ChildrenCompletedNCT03339128Phase 2
• A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide TherapeuticallyCompletedNCT02220348Phase 1